F2 and neoplasm: We further evaluated the prognostic value of VPS35 in different LIHC subgroups, and the results consistently demonstrated its significant prognostic relevance across all subsets, such as tumor status (HR = 2.15, 95% CI: 1.15–4.00, P = 0.016), gender (HR = 1.74, 95% CI: 1.11–2.74, P = 0.017) and prothrombin time (HR = 1.75, 95% CI: 1.01–3.04, P = 0.047) (Fig. S2A–S2J).